Sunday 18 October 2026
Export NRXP’s income statement to Excel — free account
NRx Pharmaceuticals, Inc.
NRXP Healthcare Biotechnology
NRx Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million. In the quarter to June 2026, EPS grew 55.1% and free cash flow fell 142.6%, each against the same quarter a year earlier.
2.60
0.11
−4.06%
Follow NRXP
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — | — | — | — | — | — |
Altman Z-Score |
(37.82) | — | — | — | — | — | — | — | — |
P/S ratio |
0.00 | — | — | — | — | — | — | — | — |
P/FCF ratio |
0.00 | — | — | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(96.18) | — | — | — | — | — | — | — | — |
P/Operating CF |
(15.62) | — | — | — | — | — | — | — | — |
P/B ratio |
0.00 | — | — | — | — | — | — | — | — |
Price to Tangible BV |
0.00 | — | — | — | — | — | — | — | — |
EV/Sales |
0.00 | — | — | — | — | — | — | — | — |
EV/EBITDA |
0.00 | — | — | — | — | — | — | — | — |
EV/Operating CF |
(4.63) | — | — | — | — | — | — | — | — |
EV/FCF |
(4.62) | — | — | — | — | — | — | — | — |
Quick Ratio |
0.28 | 0.07 | 0.24 | 1.29 | 2.32 | 0.06 | 0.00 | 0.02 | 4.82 |
Current Ratio |
0.31 | 0.15 | 0.36 | 1.66 | 2.74 | 0.06 | 0.11 | 0.05 | 5.76 |
Net Debt/EBITDA |
0.48 | (0.28) | 0.17 | 0.22 | 0.23 | 0.02 | (2.74) | (0.67) | 3.34 |
Debt/Assets |
0.00% | 180.14% | 0.00% | 40.77% | 1.53% | 26.32% | 6.09% | 0.97% | 0.00% |
Debt/Equity |
0.00 | (0.28) | 0.00 | 1.42 | 0.02 | (0.02) | 0.39 | 0.14 | 0.00 |
Asset Turnover |
0.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.49 | 0.42 | 0.72 | 1.00 | 0.11 | 0.04 | (1.94) | (7.16) | 1.29 |
Capex/Depreciation |
0.00 | 0.00 | (0.60) | (2.50) | (3.50) | (0.11) | — | — | — |
Interest Coverage |
(24.18) | (80.44) | (231.97) | (178.05) | (6,433.11) | (917.62) | (0.59) | (0.92) | (7.87) |
| 146.18% | 143.75% | 1,393.99% | (281.79%) | 3,038.41% | 267.09% | 8.17% | 1.32% | (0.15%) | |
| (344.70%) | (458.25%) | (182.06%) | (135.81%) | (1,956.18%) | (295.74%) | 0.79% | 0.09% | (0.15%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (6.41%) | (11.08%) | 0.00% |
Return on Tangible Assets |
145.86% | 135.44% | 247.94% | (389.36%) | (1,678.06%) | 119.76% | (73.87%) | (12.30%) | (23.69%) |
Average Days of Receivables |
47.97 | — | — | — | — | 0.00 | — | — | — |
Research and Development Expense of Revenue |
308.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Selling, General and Administrative Expense of Revenue |
1,066.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
18.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | — | — |
Graham Net Nets |
(0.34) | — | — | — | — | — | — | — | — |
Graham Number |
4.83 | — | — | — | — | — | — | — | — |
Earnings Yield |
(51.29%) | — | — | — | — | — | — | — | — |
Free Cash Flow Yield |
(24.34%) | — | — | — | — | — | — | — | — |
Revenue per Share |
0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.66) | (1.00) | (2.86) | (6.04) | (8.04) | (0.66) | (2.85) | (1.81) | (0.01) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(0.66) | (1.00) | (2.86) | (6.05) | (8.04) | (0.66) | (2.85) | (1.81) | (0.01) |
Cash per Share |
0.36 | 0.14 | 0.61 | 3.05 | 5.88 | 0.54 | 0.00 | 0.04 | 0.05 |
Shareholders Equity per Share |
(0.74) | (2.18) | (1.55) | 1.13 | 4.43 | (12.77) | 17.97 | 19.12 | 0.55 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.74) | (2.18) | (1.55) | 1.13 | 4.43 | (12.77) | 17.97 | 19.12 | 0.55 |
Free Cash Flow |
(14.11) | (10.64) | (21.66) | (39.76) | (37.71) | (2.27) | (0.79) | (0.47) | (0.14) |
Working Capital |
(19.69) | (18.56) | (12.16) | 10.21 | 20.79 | (43.23) | (0.55) | (0.54) | 0.44 |
Capital Expenditures |
— | — | 0.00 | (0.01) | (0.01) | 0.00 | — | — | — |
Net Current Asset Value |
(20.00) | (23.57) | (12.16) | 7.39 | 20.79 | (43.78) | (27.01) | (65.77) | (64.03) |
EV/EBIT |
0.00 | — | — | — | — | — | — | — | — |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Price to Operating Income |
0.00 | — | — | — | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
2.27 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Cash ROIC |
173.37% | 69.97% | 303.45% | (104.68%) | (77.10%) | 5.51% | (11.40%) | (8.30%) | (2.49%) |
Accounts Receivable Turnover |
2.47 | — | — | — | — | — | — | — | — |
Accounts Payable Turnover |
0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
3,086.24 | 0.00 | 0.00 | 189,435.00 | 672,877.50 | 575,422.50 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | — | — | 0.00 | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.50 | — | — | — | — | — | — | — | — |
Average Payables |
4.20 | 4.38 | 3.35 | 2.88 | 3.42 | 1.89 | 0.59 | 0.32 | 0.32 |
Average Assets |
8.30 | 5.48 | 16.57 | 29.27 | 17.84 | 17.51 | 51.44 | 70.18 | 70.18 |
Average Common Equity |
(19.58) | (17.48) | (2.16) | 14.11 | (11.48) | (19.39) | 5.00 | 5.00 | 69.51 |
Columns are period end dates